Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Interest & Investment Income (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Interest & Investment Income for 7 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 55.59% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.4 million, a 45.86% decrease, with the full-year FY2025 number at $11.4 million, down 45.86% from a year prior.
  • Interest & Investment Income was $2.0 million for Q4 2025 at Pliant Therapeutics, down from $2.8 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $6.5 million in Q3 2023 to a low of $63000.0 in Q1 2021.
  • A 5-year average of $3.1 million and a median of $3.1 million in 2022 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: surged 6623.96% in 2023, then tumbled 55.59% in 2025.
  • Pliant Therapeutics' Interest & Investment Income stood at $68000.0 in 2021, then skyrocketed by 4504.41% to $3.1 million in 2022, then surged by 99.58% to $6.2 million in 2023, then fell by 29.24% to $4.4 million in 2024, then crashed by 55.59% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Interest & Investment Income are $2.0 million (Q4 2025), $2.8 million (Q3 2025), and $3.1 million (Q2 2025).